Major depressive disorder and nutritional medicine: a review of monotherapies and adjuvant treatments
Jerome Sarris
School of Medicine, The University of Queensland, Brisbane, Australia
Search for more papers by this authorNiikee Schoendorfer
School of Medicine, The University of Queensland, Brisbane, Australia
Search for more papers by this authorDavid J Kavanagh
Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia
Search for more papers by this authorJerome Sarris
School of Medicine, The University of Queensland, Brisbane, Australia
Search for more papers by this authorNiikee Schoendorfer
School of Medicine, The University of Queensland, Brisbane, Australia
Search for more papers by this authorDavid J Kavanagh
Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia
Search for more papers by this authorAbstract
A literature review was conducted to examine the evidence for nutritional interventions in depression. It revealed a number of significant conclusions. Interestingly, more positive clinical trials were found to support adjuvant, rather than monotherapeutic, use of nutrients to treat depression. Much evidence exists in the area of adjuvant application of folic acid, S-adenosyl-methionine, omega-3, and L-tryptophan with antidepressants. Current evidence does not support omega-3 as an effective monotherapy to treat depression. However, this may be due, at least in part, to olive oil being used as the control intervention, some studies using docosahexaenoic acid alone or a higher docosahexaenoic acid to eicosapentaenoic acid ratio, and significant heterogeneity regarding depressive populations. Nevertheless, adjunctive prescription of omega-3 with antidepressants, or in people with dietary deficiency, may be beneficial. Inositol lacks evidence as an effective antidepressant and cannot be currently recommended. Evidence on the use of L-trytophan for depression is inconclusive, and additional studies utilizing a more robust methodology are required.
REFERENCES
- 1 Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008; 358: 55–68.
- 2 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th “Text Revision” ed. Arlington, VA: American Psychiatric Association; 2000.
- 3 World Health Organization. Mental and Neurological Disorders: “Depression”. Fact Sheet Geneva: WHO; 2006.
- 4 Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289: 3095–3105.
- 5 Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl. 2004; 420: 21–27.
- 6 Kessler RC, Akiskal HS, Ames M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry. 2006; 163: 1561–1568.
- 7 Parker G, Fletcher K. Treating depression with the evidence-based psychotherapies: A critique of the evidence. Acta Psychiatr Scand. 2007; 115: 352–359.
- 8 Lakhan SE, Vieira KF. Nutritional therapies for mental disorders. Nutr J. 2008; 7: 2.
- 9 Appleton KM, Peters TJ, Hayward RC, et al. Depressed mood and n-3 polyunsaturated fatty acid intake from fish: Non-linear or confounded association? Soc Psychiatry Psychiatr Epidemiol. 2007; 42: 100–104.
- 10 Morris DW, Trivedi MH, Rush AJ. Folate and unipolar depression. J Altern Complement Med. 2008; 14: 277–285.
- 11 Parker G, Gibson N, Heruc G, Rees A, Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am J Psychiatry. 2006; 163: 969–978.
- 12 Werneke U, Taylor T, Priebe S. Complementary medicines in psychiatry: Review of effectiveness and safety. Br J Psychiatry. 2006; 188: 109–121.
- 13 Appleton KM, Hayward RC, Gunnell D, et al. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: Systematic review of published trials. Am J Clin Nutr. 2006; 84: 1308–1316.
- 14 Sanchez-Villegas A, Henriquez P, Bes-Rastrollo M, Doreste J. Mediterranean diet and depression. Public Health Nutr. 2006; 9: 1104–1109.
- 15 Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H. Fatty acid composition in major depression: Decreased omega 3 fractions in cholesteryl esters and increased C20 : 4 omega 6/C20 : 5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord. 1996; 38: 35–46.
- 16 Adams PB, Lawson S, Sanigorski A, Sinclair AJ. Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids. 1996; 31: 157–161.
- 17 Dinan T, Siggins L, Scully P, O'Brien S, Ross P, Stanton C. Investigating the inflammatory phenotype of major depression: Focus on cytokines and polyunsaturated fatty acids. J Psychiatr Res. 2009; 43: 471–476.
- 18 Edwards R, Peet M, Shay J, Horrobin D. Omega-3 polyunsaturated fatty acid levels in the diet and in red blood cell membranes of depressed patients. J Affect Disord. 1998; 48: 149–155.
- 19 Tassoni D, Kaur G, Weisinger RS, Sinclair AJ. The role of eicosanoids in the brain. Asia Pac J Clin Nutr. 2008; 17: 220–228.
- 20 Williams AL, Katz D, Ali A, Girard C, Goodman J, Bell I. Do essential fatty acids have a role in the treatment of depression? J Affect Disord. 2006; 93: 117–123.
- 21 Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids. 2006; 75: 259–269.
- 22 Hamazaki K, Itomura M, Huan M, et al. Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: A randomized, placebo-controlled, double-blind trial. Nutrition. 2005; 21: 705–710.
- 23 Chalon S, Delion-Vancassel S, Belzung C, et al. Dietary fish oil affects monoaminergic neurotransmission and behavior in rats. J Nutr. 1998; 128: 2512–2519.
- 24 Delion S, Chalon S, Guilloteau D, Besnard JC, Durand G. alpha-Linolenic acid dietary deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem. 1996; 66: 1582–1591.
- 25 Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007; 68: 1056–1061.
- 26 Montgomery P, Richardson AJ. Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst Rev. 2008; CD005169.
- 27 Rogers PJ, Appleton KM, Kessler D, et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: A randomised controlled trial. Br J Nutr. 2008; 99: 421–431.
- 28 Marangell LB, Martinez JM, Zboyan HA, Kertz B, Kim HF, Puryear LJ. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry. 2003; 160: 996–998.
- 29 Grenyer BF, Crowe T, Meyer B. Fish oil supplementation in the treatment of major depression: A randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31: 1393–1396.
- 30 Garg ML, Wierzbicki AA, Thomson ABR, Clandinin MT. Dietary cholesterol and/or n-3 fatty acid modulate [Delta]9-desaturase activity in rat liver microsomes. Biochimica et Biophysica Acta (BBA) – Lipids and Lipid Metab. 1988; 962: 330–336.
- 31 Escudero A, Montilla JC, García JM, et al. Effect of dietary (n-9), (n-6) and (n-3) fatty acids on membrane lipid composition and morphology of rat erythrocytes. Biochimica et Biophysica Acta (BBA) – Lipids and Lipid Metab. 1998; 1394: 65–73.
- 32 Stoll AL, Marangell L, Severus W. The effects of olive oil on omega-3 fatty acids and mood disorders: In reply. Arch Gen Psychiatry. 2000; 57: 715.
- 33 Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH. Omega-3 treatment of childhood depression: A controlled, double-blind pilot study. Am J Psychiatry. 2006; 163: 1098–1100.
- 34 Shanahan K, Zolkowski-Wynne J, Coury D, Collins E, O'Shea J. The children's depression rating scale for normal and depressed outpatients. Clin Pediatr. 1987; 26: 245–247.
- 35 Guy W, Bonato RE. CGI: Clinical Global Impressions. Manual for the ECDEU Assessment Battery, 2nd rev edn. Chevy Chase, MD: National Institute of Mental Health; 1970: 12-1–12-6.
- 36 Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960: 23: 56–62.
- 37 Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression: Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987; 150: 782–786.
- 38 Su KP, Huang SY, Chiu TH. Omega-3 fatty acids for major depressive disorder during pregnancy: Results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2008; 69: 633–634.
- 39 Freeman MP, Hibbeln JR, Wisner KL, Brumbach BH, Watchman M, Gelenberg AJ. Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand. 2006; 113: 31–35.
- 40 Browne JC, Scott KM, Silvers KM. Fish consumption in pregnancy and omega-3 status after birth are not associated with postnatal depression. J Affect Disord. 2006; 90: 131–139.
- 41 Jazayeri S, Tehrani-Doost T, Keshavarz A, et al. Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust N Z J Psychiatry. 2008; 42: 192–198.
- 42 Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003; 13: 267–271.
- 43 Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002; 159: 477–479.
- 44 Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002; 59: 913–919.
- 45 Taylor MJ, Carney SM, Goodwin GM, Geddes JR. Folate for depressive disorders: Systematic review and meta-analysis of randomized controlled trials. J Psychopharmacol. 2004; 18: 251–256.
- 46 Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds EH. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000; 69: 228–232.
- 47 Folstein M, Liu T, Peter I, et al. The homocysteine hypothesis of depression. Am J Psychiatry. 2007; 164: 861–867.
- 48 Godfrey PS, Toone BK, Carney MW, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990; 336: 392–395.
- 49 Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: A randomised, placebo controlled trial. J Affect Disord. 2000; 60: 121–130.
- 50 Papakostas GI, Petersen T, Lebowitz BD, et al. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. 2005; 8: 523–528.
- 51 Roberts SH, Bedson E, Hughes D, et al. Folate augmentation of treatment – evaluation for depression (FolATED): Protocol of a randomised controlled trial. BMC Psychiatry. 2007; 7: 65.
- 52 Selhub J, Miller JW. The pathogenesis of homocysteinemia: Interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr. 1992; 55: 131–138.
- 53 Amsterdam JGC, Opperhuizen A. Nitric oxide and biopterin in depression and stress. Psychiatry Res. 1999; 85: 33–38.
- 54 Heseker H. Psychological disorders as early symptoms of a mild-to-moderate vitamin deficiency. Ann N Y Acad Sci. 1992; 669: 352–357.
- 55 Papakostas GI, Alpert JE, Fava M. S-adenosyl-methionine in depression: A comprehensive review of the literature. Curr Psychiatry Rep. 2003; 5: 460–466.
- 56 Williams AL, Girard C, Jui D, Sabina A, Katz DL. S-adenosylmethionine (SAMe) as treatment for depression: A systematic review. Clin Invest Med. 2005; 28: 132–139.
- 57 Agnoli A, Andreoli V, Casacchia M, Cerbo R. Effect of s-adenosyl-l-methionine (SAMe) upon depressive symptoms. J Psychiatr Res. 1976; 13: 43–54.
- 58 Alpert JE, Papakostas G, Mischoulon D, et al. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: An open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004; 24: 661–664.
- 59 Pancheri P, Scapicchio P, Chiaie RD. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder. Int J Neuropsychopharmacol. 2002; 5: 287–294.
- 60 Salmaggi P, Bressa GM, Nicchia G, Coniglio M, La Greca P, Le Grazie C. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychother Psychosom. 1993; 59: 34–40.
- 61 Berlanga C, Ortega-Soto HA, Ontiveros M, Senties H. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine. Psychiatry Res. 1992; 44: 257–262.
- 62 Rosenbaum JF, Fava M, Falk WE, et al. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand. 1990; 81: 432–436.
- 63 Levine J, Barak Y, Gonzalves M, et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry. 1995; 152: 792–794.
- 64 Levine J, Mishori A, Susnosky M, Martin M, Belmaker RH. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biol Psychiatry. 1999; 45: 270–273.
- 65 Nemets B, Mishory A, Levine J, Belmaker RH. Inositol addition does not improve depression in SSRI treatment failures. J Neural Transm. 1999; 106: 795–798.
- 66 Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: A comprehensive review of findings. Curr Psychiatry Rep. 2007; 9: 449–459.
- 67 Hood SD, Bell CJ, Nutt DJ. Acute tryptophan depletion. Part I: Rationale and methodology. Aust N Z J Psychiatry. 2005; 39: 558–564.
- 68 Porter RJ, Mulder RT, Joyce PR, Luty SE. Tryptophan and tyrosine availability and response to antidepressant treatment in major depression. J Affect Disord. 2005; 86: 129–134.
- 69 Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: A review of its antidepressant efficacy and adverse effects. J Clin Psychopharmacol. 1987; 7: 127–137.
- 70 Thomson J, Rankin H, Ashcroft GW, Yates CM, McQueen JK, Cummings SW. The treatment of depression in general practice: A comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo. Psychol Med. 1982; 12: 741–751.
- 71 Glassman AH, Platman SR. Potentiation of a monoamine oxidase inhibitor by tryptophan. J Psychiatr Res. 1969; 7: 83–88.
- 72 Nardini M, De Stefano R, Iannuccelli M, Borghesi R, Battistini N. Treatment of depression with L-5-hydroxytryptophan combined with chlorimipramine, a double-blind study. Int J Clin Pharmacol Res. 1983; 3: 239–250.
- 73 Walinder J, Skott A, Carlsson A, Nagy A, Bjorn-Erik R. Potentiation of the antidepressant action of clomipramine by tryptophan. Arch Gen Psychiatry. 1976; 33: 1384–1389.
- 74 Coppen A, Shaw DM, Farrell JP. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet. 1963; 1: 79–81.
- 75 Levitan RD, Shen JH, Jindal R, Driver HS, Kennedy SH, Shapiro CM. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: Antidepressant and hypnotic effects. J Psychiatry Neurosci. 2000; 25: 337–346.
- 76 Shaw DM, Macsweeney DA, Hewland R, Johnson AL. Tricyclic antidepressants and tryptophan in unipolar depression. Psychol Med. 1975; 5: 276–278.
- 77 Ayuso Gutierrez JL, Lopez-Ibor Alino JJ, Montejo Iglesias L. Tryptophan and amitriptyline in the treatment of depression (double blind study). Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1973; 1: 471–476.
- 78 Praag HM. In search of the mode of action of antidepressants 5-HTP/tyrosine mixtures in depressions. Neuropharmacology. 1983; 22: 433–440.
- 79 Filippini G, Costa C, Bertazzo A. Recent advances in tryptophan research; tryptophan and serotonin pathways. Experiment Biol Med. 1996; 398: 762.
- 80 Wurtman R, Wurtman J. Carbohydrates and depression. Sci Am. 1989; 260: 68–75.
- 81 Groff J, Gropper S. Advanced Nutrition and Human Metabolism, 3rd edn. London: Wadsworth; 2000.
- 82 Guilarte TR. Effect of vitamin B-6 nutrition on the levels of dopamine, dopamine metabolites, dopa decarboxylase activity, tyrosine, and GABA in the developing rat corpus striatum. Neurochem Res. 1989; 14: 571–578.